TY - JOUR T1 - Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial PY - -0001/11/30 AU - Goodyear CS AU - Patel A AU - Barnes E AU - willicombe M AU - Siebert S AU - de Silva TI AU - Snowden JA AU - Lim S AU - Bowden S AU - Billingham LJ AU - Richter AG et al ED - Y2 - 2025/03/15 ER -